These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 28043720

  • 1. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Yang Y, Zhang Y, Yang L, Zhao L, Si L, Zhang H, Liu Q, Zhou J.
    Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC, Peng X, Ma YC, Ji YC, Chen DQ, Zheng MY, Zhao DM, Cheng MS, Geng MY, Shen JK, Ai J, Xiong B.
    Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
    Zhao Y, Zhang J, Zhuang R, He R, Xi J, Pan X, Shao Y, Pan J, Sun J, Cai Z, Liu S, Huang W, Lv X.
    Bioorg Med Chem; 2017 Jun 15; 25(12):3195-3205. PubMed ID: 28412159
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX, Liu X, Xu S, Tang Q, Duan Y, Xiao Z, Zhi J, Jiang L, Zheng P, Zhu W.
    Eur J Med Chem; 2017 Dec 01; 141():538-551. PubMed ID: 29107421
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D, Wang Y, Ma Y, Xiong B, Ai J, Chen Y, Geng M, Shen J.
    ChemMedChem; 2012 Jun 01; 7(6):1057-70. PubMed ID: 22581753
    [Abstract] [Full Text] [Related]

  • 6. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
    Damghani T, Moosavi F, Khoshneviszadeh M, Mortazavi M, Pirhadi S, Kayani Z, Saso L, Edraki N, Firuzi O.
    Sci Rep; 2021 Feb 11; 11(1):3644. PubMed ID: 33574356
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W, Xu S, Duan Y, Liu X, Li X, Wang C, Zhao B, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Feb 10; 145():315-327. PubMed ID: 29331754
    [Abstract] [Full Text] [Related]

  • 8. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L, Zhao J, Zhang B, Lu T, Chen Y.
    Eur J Med Chem; 2018 Apr 25; 150():809-816. PubMed ID: 29602036
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z, Shi J, Zhu X, Zhao W, Gong Y, Hao X, Hou Y, Liu Y, Ding S, Liu J, Chen Y.
    Bioorg Chem; 2020 Dec 25; 105():104371. PubMed ID: 33075664
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Tang Q, Wang L, Tu Y, Zhu W, Luo R, Tu Q, Wang P, Wu C, Gong P, Zheng P.
    Bioorg Med Chem Lett; 2016 Apr 01; 26(7):1680-4. PubMed ID: 26923692
    [Abstract] [Full Text] [Related]

  • 11. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Wang J, Tang Q, Wu C, Zhao Y, Zheng P.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1749-56. PubMed ID: 26964675
    [Abstract] [Full Text] [Related]

  • 12. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J, Li J, Zhang J, Shi J, Ding S, Liu Y, Chen Y, Liu J.
    Anticancer Agents Med Chem; 2020 Apr 15; 20(5):559-570. PubMed ID: 31893997
    [Abstract] [Full Text] [Related]

  • 13. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 14. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD, Liu H, Xu ZL, Jin Y, Peng X, Yao YM, Geng M, Long YQ.
    Bioorg Med Chem Lett; 2015 Feb 01; 25(3):708-16. PubMed ID: 25529740
    [Abstract] [Full Text] [Related]

  • 15. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X, Li HJ, Fang SB, Li QY, Wu YC.
    Eur J Med Chem; 2020 May 01; 193():112241. PubMed ID: 32200199
    [Abstract] [Full Text] [Related]

  • 16. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W.
    Chem Biol Drug Des; 2018 Jul 01; 92(1):1301-1314. PubMed ID: 29575727
    [Abstract] [Full Text] [Related]

  • 17. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q, Wang L, Duan Y, Wang W, Huang S, Zhi J, Jia S, Zhu W, Wang P, Luo R, Zheng P.
    Eur J Med Chem; 2017 Jun 16; 133():97-106. PubMed ID: 28384549
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 19. Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors.
    Nishii H, Chiba T, Morikami K, Fukami TA, Sakamoto H, Ko K, Koyano H.
    Bioorg Med Chem Lett; 2010 Feb 15; 20(4):1405-9. PubMed ID: 20093027
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.